[1]
|
Rawther, T. and Tabet, F. (2019) Biology, Pathophysiology and Current Therapies That Affect Lipoprotein (a) Levels. The Journal of Molecular and Cellular Cardiology, 131, 1-11. https://doi.org/10.1016/j.yjmcc.2019.04.005
|
[2]
|
Labudovic, D., Kostovska, I., Trajkovska, K.T., et al. (2019) Lipoprotein(a)—Link between Atherogenesis and Thrombosis. Prague Medical Report, 120, 39-51. https://doi.org/10.14712/23362936.2019.9
|
[3]
|
Nicholls, S.J., Tang, W.H.W., Scoffone, H., et al. (2010) Lipoprotein(a) Levels and Long-Term Cardiovascular Risk in the Contemporary Era of Statin Therapy. Journal of Lipid Research, 51, 3055-3061.
https://doi.org/10.1194/jlr.M008961
|
[4]
|
Danesh, J., Collins, R. and Peto, R. (2000) Lipoprotein(a) and Coronary Heart Disease. Meta-Analysis of Prospective Studies. Circulation, 102, 1082-1085. https://doi.org/10.1161/01.CIR.102.10.1082
|
[5]
|
Rifai, N., Ma, J., Sacks, F.M, et al. (2004) Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians’ Health Study. Clinical Chemistry, 50 1364-1371. https://doi.org/10.1373/clinchem.2003.030031
|
[6]
|
Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 64, e139-e228.
|
[7]
|
Giaccari, A. and Inzucchi, S.E., for the ADA/EASD Position Statement Group (2012) Comment on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: 1364-1379. Diabetes Care, 35, e72-e73. https://doi.org/10.2337/dc12-1184
|
[8]
|
Zekavat, S.M., Ruotsalainen, S., Handsaker, R.E., et al. (2018) Deep Coverage Whole Genome Sequences and Plasma Lipoprotein(a) in Individuals of European and African Ancestries. Nature Communications, 9, Article No. 2606.
https://doi.org/10.1038/s41467-018-04668-w
|
[9]
|
Tada, H., Kawashiri, M.A. and Yamagishi, M. (2017) Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 24, 452-461.
https://doi.org/10.5551/jat.RV17002
|
[10]
|
Hiraiwa, H., Morimoto, R., Okumura, T., et al. (2019) A Survival Case of a Young Adult Patient with ST-Elevated Myocardial Infarction with High levels of Lipoprotein(a). Journal of Cardiology Cases, 19, 207-210.
https://doi.org/10.1016/j.jccase.2019.02.004
|
[11]
|
Khera, A.V., Everett, B.M., Caulfield, M.P., et al. (2014) Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, 129, 635-642.
https://doi.org/10.1161/CIRCULATIONAHA.113.004406
|
[12]
|
宋佳希, 汪俊军. 关注非传统危险因子在心血管疾病残余风险评估中的作用[J]. 中华检验医学杂志, 2019(8): 595-601.
|
[13]
|
Schmidt, K., Noureen, A. and Kronenberg, F. (2016) Structure, Function, and Genetics of Lipoprotein (a). Journal of Lipid Research, 57, 1339-1359. https://doi.org/10.1194/jlr.R067314
|
[14]
|
Enas, E.A., Varkey, B., Dharmarajan, T.S., et al. (2019) Lipoprotein(a): An Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112.
https://doi.org/10.1016/j.ihj.2019.03.004
|
[15]
|
Yoshida, H. (2019) Clinical Impact and Significance of Serum Lipoprotein (a) Levels on Cardiovascular Risk in Patients with Coronary Artery Disease. Circulation Journal, 83, 967-968. https://doi.org/10.1253/circj.CJ-19-0221
|
[16]
|
Ellis, K.L., Chakraborty, A., Moses, E.K. and Watts, G.F. (2019) To Test, or Not to Test: That Is the Question for the Future of Lipoprotein(a). Expert Review of Cardiovascular Therapy, 17, 241-250.
https://doi.org/10.1080/14779072.2019.1596799
|
[17]
|
Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. Journal of the American College of Cardiology, 73, 2150-2162.
https://doi.org/10.1016/j.jacc.2019.01.070
|
[18]
|
Holmes, D.T., Schick, B.A., Humphries, K.H. and Frohlich, J. (2005) Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia. Clinical Chemistry, 51, 2067-2073.
https://doi.org/10.1373/clinchem.2005.055228
|
[19]
|
Zhou, B.-Y., Sun, D., Wang, C., et al. (2019) Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. Heart, Lung and Circulation, 28, 1009-1017. https://doi.org/10.1016/j.hlc.2018.05.190
|
[20]
|
谷阳, 于昆, 徐琢, 葛培兵, 张喜文. 脂蛋白(a)对非ST段抬高型急性冠状动脉综合征患者风险评估的价值[J]. 中华老年心脑血管病杂志, 2018, 20(2): 149-152.
|
[21]
|
马煜盛. 脂蛋白(a)与冠心病风险及严重程度关系的研究[D]: [博士学位论文]. 广州: 南方医科大学, 2019.
|